Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 7,400 shares, a decrease of 23.7% from the October 15th total of 9,700 shares. Based on an average daily volume of 10,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.3% of the company’s stock are short sold.

Traws Pharma Stock Down 10.6 %

Shares of Traws Pharma stock opened at $4.99 on Friday. Traws Pharma has a 12 month low of $4.44 and a 12 month high of $27.50. The firm has a market cap of $9.13 million, a price-to-earnings ratio of -0.04 and a beta of 1.41.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($4.87) earnings per share (EPS) for the quarter. Traws Pharma had a negative return on equity of 144.95% and a negative net margin of 60,641.14%. The firm had revenue of $0.06 million during the quarter. Sell-side analysts anticipate that Traws Pharma will post -146 EPS for the current year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.